萊斯康製藥 LXRX 深 滬
等待開盤 04-01 09:30:00 美东时间
1.56
+0.050
+3.31%
華盛通- 最 高1.5879
- 今 開1.52
- 成交量 175.49万股
- 最 低 1.52
- 昨 收 1.51
- 總市值 6.61亿
- 52周最高 1.83
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 0.48
- 委 比 -4.10%
- 總股本 4.24亿
- 歷史最高 22.96
- 量 比 0.62
- 振 幅 4.50%
- 歷史最低 0.2836
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
03-30 20:04
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide
03-23 19:38
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851, developed by Novo Nordisk and licensed from Lexicon Pharmaceuticals, is a first-in-class oral non-incretin candidate for obesity and metabolic disorders. Novo Nordisk has initiated a Phase 1 study, and Lexicon has received a second $10 million milestone payment, with potential total payments up to $1 billion plus royalties. Trials in 96 participants are evaluating safety, tolerability, and efficacy. LX9851 inhibits ACSL5 and activates the...
03-23 11:30
Lexicon Pharmaceuticals Says sotagliflozin Improves Cardiometabolic Outcomes In Type 1 Diabetes Regardless Of Kidney Function; New Analysis To Be Presented At ATTD 2026
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on
03-11 20:12
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Lexicon Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Lexicon Pharmaceuticals (NASDAQ:LXRX) just disclosed its Q4 earnings on Thursda...
03-05 20:02
BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04
BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04 Mar 05 (Reuters) - Lexicon Pharmaceuticals Q4 operating income USD -14.78 million. Q4 product revenue USD 1.055 million Q4 basic EPS USD -0.04 Q4 net income USD -15.53 million Q4 operating expenses USD 20.273 million
03-05 19:59
Lexicon posts Q4 net loss of USD 15.5 million (54.0% narrower)
Lexicon posts Q4 net loss of USD 15.5 million (54.0% narrower) Lexicon reported Q4 FY2025 total revenues of USD 5.5 million (USD 4.3 million licensing revenue and USD 1.1 million net product revenue from INPEFA). Q4 R&D expenses were USD 11.3 million (-57.6%) and SG&A expenses were USD 8.8 million (
03-05 19:59
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
